Gregory Duncan - Dogwood Therapeutics, Chairman CEO
DWTX Stock | 2.56 0.04 1.54% |
Chairman
Gregory Duncan is Chairman CEO of Dogwood Therapeutics,
Age | 59 |
Address | 44 Milton Avenue, Alpharetta, GA, United States, 30009 |
Phone | 866 620 8655 |
Web | https://www.dwtx.com |
Gregory Duncan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Gregory Duncan against Dogwood Therapeutics, stock is an integral part of due diligence when investing in Dogwood Therapeutics,. Gregory Duncan insider activity provides valuable insight into whether Dogwood Therapeutics, is net buyers or sellers over its current business cycle. Note, Dogwood Therapeutics, insiders must abide by specific rules, including filing SEC forms every time they buy or sell Dogwood Therapeutics,'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Gregory Duncan over three months ago Acquisition by Gregory Duncan of 801 shares of Virios Therapeutics at 7.8 subject to Rule 16b-3 | ||
Gregory Duncan over six months ago Acquisition by Gregory Duncan of 138835 shares of Virios Therapeutics at 0.357 subject to Rule 16b-3 | ||
Gregory Duncan over a year ago Purchase by Gregory Duncan of 25000 shares of Virios Therapeutics | ||
Gregory Duncan over a year ago Acquisition by Gregory Duncan of 410000 shares of Virios Therapeutics subject to Rule 16b-3 |
Similar Executives
Found 1 records | CHAIRMAN Age | ||
Mark Emalfarb | Dyadic International | 68 |
Dogwood Therapeutics, Leadership Team
Elected by the shareholders, the Dogwood Therapeutics,'s board of directors comprises two types of representatives: Dogwood Therapeutics, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dogwood. The board's role is to monitor Dogwood Therapeutics,'s management team and ensure that shareholders' interests are well served. Dogwood Therapeutics,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dogwood Therapeutics,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
Gregory Duncan, Chairman CEO | ||
Carol Duffy, Chief Advisor | ||
William MD, Founder Board | ||
Ralph MPH, Senior Operations | ||
Angela Walsh, Secretary Officer |
Dogwood Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dogwood Therapeutics, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Net Income | (5.3 M) | ||||
Total Debt | 358.55 K | ||||
Total Asset | 4.17 M | ||||
Retained Earnings | (61.47 M) | ||||
Working Capital | 3.81 M | ||||
Net Asset | 4.17 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Dogwood Stock Analysis
When running Dogwood Therapeutics,'s price analysis, check to measure Dogwood Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dogwood Therapeutics, is operating at the current time. Most of Dogwood Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Dogwood Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dogwood Therapeutics,'s price. Additionally, you may evaluate how the addition of Dogwood Therapeutics, to your portfolios can decrease your overall portfolio volatility.